Paper Details

  1. Home
  2. Paper Details

A systematic review of dual targeting in HER2-positive breast cancer.

Author: KümlerIben, NielsenDorte Lisbet, TuxenMalgorzata K

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review examines the efficacy and toxicity of dual targeting strategies in HER2-positive breast cancer, considering the development of therapeutic agents to potentiate the effect of trastuzumab or target cells that have become resistant to trastuzumab.
Paper Details　
Original Abstract of the Article :
Human epidermal growth factor receptor 2 (HER2) is overexpresed in 15-20% of all breast cancers. Treatment with trastuzumab has led to an improved outcome and prolonged survival of HER2-positive breast cancer patients and today the drug is established as standard of care in both the adjuvant and met...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ctrv.2013.09.002

データ提供：米国国立医学図書館（NLM）

Targeting HER2 in Breast Cancer: A Dual Approach

Breast cancer, a complex and multifaceted disease, demands innovative therapeutic strategies. This review explores the role of dual targeting in HER2-positive breast cancer, focusing on the potential of combining therapies to improve treatment outcomes. Researchers, like skilled engineers designing intricate structures, delve into the intricate world of HER2, a protein implicated in breast cancer development. The review examines the efficacy and toxicity of various dual targeting approaches, highlighting the potential of combining therapies to enhance the effectiveness of trastuzumab, a widely used HER2-targeted drug. The review underscores the importance of ongoing research and development in this area, seeking to overcome drug resistance and improve the lives of patients with HER2-positive breast cancer.

Beyond Single Targets: A Collaborative Approach to Breast Cancer Therapy

The review highlights the promise of dual targeting in breast cancer, suggesting that combining therapies, like weaving together threads of different colors, can enhance treatment effectiveness and potentially overcome drug resistance. This approach, like building upon a sturdy foundation, leverages the strengths of multiple therapies to achieve better outcomes for patients.

Empowering Patients: A Collaborative Approach to Breast Cancer Care

This review underscores the importance of collaborative care in managing breast cancer. By working closely with their healthcare providers, patients can explore various treatment options, including dual targeting approaches, and make informed decisions that align with their individual needs and preferences. The review emphasizes the importance of ongoing communication, research, and patient empowerment in achieving optimal outcomes for breast cancer patients.

Dr.Camel's Conclusion

This review provides a comprehensive overview of dual targeting strategies in HER2-positive breast cancer, highlighting the potential of combining therapies to improve treatment outcomes. The review underscores the importance of ongoing research and development in this area, seeking to overcome drug resistance and improve the lives of patients with HER2-positive breast cancer.

Date :
  1. Date Completed 2014-01-27
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

24080156

DOI: Digital Object Identifier

10.1016/j.ctrv.2013.09.002

Related Literature

Article Analysis
・Side Effects of neratinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.